For medicines: For risks and side effects, read the package insert and consult your doctor or your pharmacy
If a patient experiences severe symptoms, such as intense pain or high fever, visiting an urgent care facility can be a good option
Subcutaneous injections can be less painful and easier to do yourself
RENEW is the planned monotherapy Phase 3 program
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
Similarly, sermorelin is a GHRH analog that was FDA approved for children with growth hormone deficiency